

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

- Company to present at several partnering and investor forums
- Preclinical data with oral T-cell immunotherapy platform to be presented at EORTC-NCI-AACR Symposium

Basel (Switzerland) and Mannheim (Germany), October 26, 2016 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that management will be presenting at several upcoming events in October and November.

Equity Forum 2016: Cancer Immunotherapy – a STANDARD emerging!

VAXIMM will provide a corporate and scientific overview at this event on October 26th in Heilbronn, Germany. Jointly organized by the Investment Lab Heilbronn and Apus Capital, the forum brings together leading biotech and pharmaceutical players in the field of cancer immunotherapy. [Click here](#) for more information about this event.

BIO-Europe® - 2016 - 22nd Annual International Partnering Conference

This conference is being held November 7-9 in Cologne, Germany. VAXIMM's Chief Executive Officer, Matthias Schroff, will provide an update on the Company's business strategy and its lead program, VXM01 oral T-cell immunotherapy, currently in clinical development for the treatment of colorectal cancer, glioblastoma and pancreatic cancer. The Company's presentation will take place on November 9th at 10:00 AM. More information on this conference is available [here](#).

German Equity Forum (Deutsches Eigenkapitalforum)

This capital markets conference will take place November 21-23 in Frankfurt/Main, Germany. Matthias Schroff, CEO, will present the corporate strategy as part of the private growth company track on November 23rd at 10:30 AM. More information on this conference is available [here](#).

In addition, preclinical data from VAXIMM's oral T-cell immunotherapy platform will be presented at an important scientific conference later this fall:

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

A poster entitled, *Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m*, will be presented by Dr. Sebastien Wieckowski, VAXIMM AG, during the Immunotherapy poster session on November 30th. This scientific conference is being held November 29 - December 2 in Munich, Germany. The abstract will be available online on November 15th at www.ecco-org.eu/ENA.

About VAXIMM:

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target specific structures of the tumor. VAXIMM's lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM's investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's clinical operations. For more information, please see www.vaximm.com.

Contact:

Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
Email: info@vaximm.com

Media Inquiries:

MC Services AG
Katja Arnold, Shaun Brown
Email: vaximm@mc-services.eu
Tel: +49 89 210228-0